Results

1–10 of 27 results for growth

Utility of Outer Retinal Tubulation in Predicting Lesion Growth in Subfoveal and Nonsubfoveal Geographic Atrophy
Srinivas Sai A Kondapalli, MD
Annual Meeting Talks
2023
Systemic Adverse Events in Patients With Diabetes Treated With Intravitreal Antivascular Endothelial Growth Factor Injections
Roomasa Channa, MD
Annual Meeting Talks
2023
Expert Panel: Faricimab and Aflibercept 8 mg in AMD
John T. Thompson, MD
Andrew A. Moshfeghi, MD, MBA, FASRS
Manjot K Gill, MD, FASRS
Christina Y Weng, MD, MBA, FASRS
Ferhina S Ali, MD, MPH
Ian Pearce, MB ChB BSc FRCOPHTH
Annual Meeting Talks
2024
Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy
Judy E. Kim, MD, FASRS
Chirag D. Jhaveri, MD, FASRS
Michael S. Ip, MD
Arshad M. Khanani, MD, MA, FASRS
Jordana G Fein, MD, MS
Dennis M. Marcus, MD
Diana V Do, MD, FASRS
Annual Meeting Talks
2024
Intravitreal Therapeutics Utilization in 2023
Anton M Kolomeyer, MD, PhD
Annual Meeting Talks
2024
Factors Associated With the Development of Exudation in Treatment-Naïve Eyes With Nonexudative Macular Neovascularization
HAN JOO CHO, MD
Annual Meeting Talks
2024
Predictive Role of Outer Retinal Tubulation in Lesion Growth for Subfoveal and Nonsubfoveal Geographic Atrophy
Srinivas Sai A Kondapalli, MD
Annual Meeting Talks
2024
Baseline Ellipsoid Zone Integrity Features as Predictors of Geographic Atrophy Growth Rate in the Phase 3 GATHER Clinical Trials
Katherine E Talcott, MD
Annual Meeting Talks
2024
Prophylactic Intraocular Pressure–Lowering Measures in Antivascular Endothelial Growth Factor Therapy: Systematic Review and Meta-Analysis
Parnian Arjmand, MD, MSc, FRCSC, DABO
Annual Meeting Talks
2022
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024